DR. ANDREW JAMES HOLMAN, MD
Osteopathic Medicine at Talbot Rd, Seattle, WA
License number
Washington MD00027644
Category
Osteopathic Medicine
Type
Rheumatology
Address
Address
4300 Talbot Rd S SUITE 101, Seattle, WA 98055
Phone
(425) 235-9500
(425) 235-9555 (Fax)
(425) 235-9055
(425) 235-9555 (Fax)
(425) 235-9055
Personal information
See more information about ANDREW JAMES HOLMAN at radaris.comName
Address
Phone
19658 Marine View Dr SW, Normandy Park, WA 98166
1224 Denny Way, Seattle, WA 98109
19658 Marine View Dr SW, Seattle, WA 98166
4011 Talbot Rd S, Renton, WA 98055
5870 Park Point Dr NE, Seattle, WA 98115
Professional information
Administration Of Sleep Restorative Agents
US Patent:
2008008, Apr 17, 2008
Filed:
Apr 17, 2007
Appl. No.:
11/736406
Inventors:
Andrew Holman - Seattle WA, US
International Classification:
A61K 31/428, A61K 31/196, A61K 31/404, A61K 31/437, A61K 31/5025, A61K 31/52, A61K 31/56, A61K 38/00, A61K 38/21, A61P 37/06, A61P 25/20, A61K 39/395, A61K 38/13, A61K 31/675, A61K 31/5513, A61K 31/519, A61K 31/4427, A61K 31/433, A61K 31/42
US Classification:
424085400, 424143100, 514110000, 514012000, 514171000, 514221000, 514249000, 514259300, 514263200, 514291000, 514300000, 514361000, 514367000, 514378000, 514418000, 514561000, 514009000
Abstract:
The present invention provides methods and compositions for increasing the efficacy of a therapeutic agent administered to a subject. A steep restorative agent is co-administered to the subject along with the therapeutic agent, whereby the efficacy of the therapeutic agent is increased.
Andrew James Holman, Renton WA
Specialties:
Rheumatologist
Address:
4300 Talbot Rd S, Renton, WA 98055
Education:
University of Missouri, School of Medicine (Columbia) - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Rheumatology (Internal Medicine)
Administration Of Sleep Restorative Agents
US Patent:
2002016, Nov 7, 2002
Filed:
Mar 5, 2002
Appl. No.:
10/091744
Inventors:
Andrew Holman - Seattle WA, US
International Classification:
A61K031/515
US Classification:
514/270000, 514/419000
Abstract:
The present invention provides methods and compositions for increasing the efficacy of a therapeutic agent administered to a subject. A sleep restorative agent is co-administered to the subject along with the therapeutic agent, whereby the efficacy of the therapeutic agent is increased.
Andrew James Holman, Renton WA
Specialties:
Internal Medicine, Rheumatology, Pediatrics
Work:
Pacific Rheumatology Associates
4300 Talbot Rd S, Renton, WA 98055
4300 Talbot Rd S, Renton, WA 98055
Education:
University of Missouri at Columbia (1987)
Methods For Determining Whether To Provide An Inhibitor Of Sympathetic Nervous System Activity To A Human Being Suffering From An Autoimmune Disease Or Fibryomyalgia
US Patent:
7146205, Dec 5, 2006
Filed:
May 19, 2003
Appl. No.:
10/441922
Inventors:
Andrew J. Holman - Seattle WA, US
Assignee:
CNS-Rheumatology, Inc. - Seattle WA
International Classification:
A61B 5/04
US Classification:
600515
Abstract:
The present invention provides methods for determining whether to provide an inhibitor of sympathetic nervous system activity to a human being suffering from an autoimmune disease and/or fibromyalgia. The methods of this aspect of the invention each include the steps of: (a) measuring the heart rate variability of a human being suffering from an autoimmune disease or fibromyalgia, to yield heart rate variability data; (b) analyzing the heart rate variability data to determine whether there is excessive sympathetic nervous system activity in the heart of the human being; and (c) providing an inhibitor of sympathetic nervous system activity to the human being if there is excessive sympathetic nervous system activity in the heart of the human being.
Use Of Dopamine D2/D3 Receptor Agonists To Treat Fibromyalgia
US Patent:
6277875, Aug 21, 2001
Filed:
Jul 17, 2000
Appl. No.:
9/617177
Inventors:
Andrew J. Holman - Seattle WA
International Classification:
A61K 3425, A61K 3140
US Classification:
514367
Abstract:
The present invention is directed to metho s for the treatment of human patients afflicted with fibromyalgia using a non-ergot dopamine receptor D2/D3 agonist. In particular, patients are treated with a therapeutically effective amount of tetrahydro-benzthiazole or 3(H)-indolone compounds that are dopamine agonists. More specifically, the compounds 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole or 4-[2-(dipropylamino)-ethyl]-1,3-dihydro-2H-indol-2-one are administered to fibromyalgia patients to reduce the musculoskeletal pain symptoms associated with fibromyalgia.
Use Of Dopamine D2/D3 Receptor Agonists To Treat Fibromyalgia
US Patent:
6300365, Oct 9, 2001
Filed:
May 7, 2001
Appl. No.:
9/850901
Inventors:
Andrew J. Holman - Seattle WA
International Classification:
A61K 3140
US Classification:
514418
Abstract:
The present invention is directed to methods for the treatment of human patients afflicted with fibromyalgia using a non-ergot dopamine receptor D2/D3 agonist. In particular, patients are treated with a therapeutically effective amount of tetrahydro-benzthiazole or 3(H)-indolone compounds that are dopamine agonists. More specifically, the compounds 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole or 4-[2-(dipropylamino)-ethyl]-1,3-dihydro-2H-indol-2-one are administered to fibromyalgia patients to reduce the musculoskeletal pain symptoms associated with fibromyalgia.